Assess Efficacy of HB-adMSCs to treat COVID-19 patients.Primary endpoints: detect change from baseline in inflammatory markers (IL-6, IL-10, TNF-alpha, C Reactive protein), improving oxygenation, and decreasing time to return to room air (RTRA). This evidence concerns the gene CRP and COVID-19.